Antiplatelet Agents Practice Test

The half-life of urokinase is approximately 15 minutes. This relatively short half-life is significant in a clinical context because it informs healthcare providers about the duration of urokinase's action in the bloodstream. When urokinase is administered as a thrombolytic agent, its quick onset and short duration mean that it can effectively dissolve clots, but close monitoring of the patient is necessary due to the need for recurrent dosing or additional interventions. Understanding the half-life is crucial for optimizing treatment regimens, ensuring that the drug remains effective while minimizing potential side effects or complications.